# An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

> **NCT05686629** · PHASE2 · UNKNOWN · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Novel COVID-19-Infected Pneumonia

## Interventions

- **DRUG:** Jaktinib hydrochloride tablets

## Key facts

- **NCT ID:** NCT05686629
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04
- **Primary completion:** 2025-02
- **Final completion:** 2025-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686629, "An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05686629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*